[go: up one dir, main page]

MX2021012544A - Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales. - Google Patents

Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.

Info

Publication number
MX2021012544A
MX2021012544A MX2021012544A MX2021012544A MX2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A MX 2021012544 A MX2021012544 A MX 2021012544A
Authority
MX
Mexico
Prior art keywords
treatment
pharmaceutical compositions
novel compounds
kidney diseases
prophylaxis
Prior art date
Application number
MX2021012544A
Other languages
English (en)
Inventor
Reginald Christophe Xavier Brys
Der Geest Ronald Van
Katja Els Conrath
Thierry Jean-Claude Marie Christophe
Original Assignee
Galapagos Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv filed Critical Galapagos Nv
Publication of MX2021012544A publication Critical patent/MX2021012544A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención describe los compuestos de acuerdo con la Fórmula I: (ver Fórmula) En donde R1 es como se define en este documento. La presente invención se refiere a compuestos, métodos para su producción, composiciones farmacéuticas que comprenden los mismos y métodos de tratamiento que usan los mismos, para la profilaxis y/o el tratamiento que pueden ser útiles en la profilaxis y/o el tratamiento de la enfermedad poliquística renal (PKD), mediante la administración del compuesto de la invención.
MX2021012544A 2019-04-24 2020-04-21 Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales. MX2021012544A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1905711.6A GB201905711D0 (en) 2019-04-24 2019-04-24 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases
PCT/EP2020/061083 WO2020216740A1 (en) 2019-04-24 2020-04-21 Novel compounds and pharmaceutical compositions thereof for the treatment of kidney diseases

Publications (1)

Publication Number Publication Date
MX2021012544A true MX2021012544A (es) 2021-11-12

Family

ID=66810218

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021012544A MX2021012544A (es) 2019-04-24 2020-04-21 Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.

Country Status (16)

Country Link
US (1) US12383544B2 (es)
EP (1) EP3958863B1 (es)
JP (1) JP7543304B2 (es)
KR (1) KR20220004111A (es)
CN (1) CN113727711A (es)
AU (1) AU2020263869A1 (es)
BR (1) BR112021021117A2 (es)
CA (1) CA3137445A1 (es)
ES (1) ES2982398T3 (es)
GB (1) GB201905711D0 (es)
IL (1) IL287392A (es)
MA (1) MA55752A (es)
MX (1) MX2021012544A (es)
PH (1) PH12021552680A1 (es)
SG (1) SG11202111739VA (es)
WO (1) WO2020216740A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025096453A1 (en) * 2023-10-30 2025-05-08 Vertex Pharmaceuticals Incorporated Compounds for the treatment of kidney disease
WO2025121320A1 (ja) * 2023-12-04 2025-06-12 国立大学法人山口大学 多発性嚢胞腎の予防又は治療剤
WO2025201305A1 (en) * 2024-03-26 2025-10-02 Alebund Pharmaceuticals (Hong Kong) Limited Method for treating autosomal dominant polycystic kidney disease

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7514463B2 (en) * 2004-08-20 2009-04-07 University Of Kansas Lonidamine analogues and their use in male contraception and cancer treatment
US8362031B2 (en) * 2004-08-20 2013-01-29 University Of Kansas Lonidamine analogues and treatment of polycystic kidney disease
IN2012DN00719A (es) * 2009-08-10 2015-06-19 Univ California
TWI633887B (zh) * 2012-05-31 2018-09-01 大塚製藥股份有限公司 用於預防及／或治療多囊性腎臟病之藥物
WO2016073470A1 (en) * 2014-11-04 2016-05-12 The University Of Kansas Lkb1-ampk activators for therapeutic use in polycystic kidney disease
TW201735769A (zh) 2015-10-09 2017-10-16 盧森堡商艾伯維公司 經取代之吡唑并［３，４－ｂ］吡啶－６－羧酸及使用方法
US9890158B2 (en) * 2015-10-09 2018-02-13 Abbvie S.Á.R.L. N-sulfonylated pyrazolo[3,4-b]pyridin-6-carboxamides and method of use
JP2018529707A (ja) * 2015-10-09 2018-10-11 アッヴィ・エス・ア・エール・エル 嚢胞性線維症の処置のための新規な化合物
JP2020525446A (ja) * 2017-06-21 2020-08-27 ザ・ジョンズ・ホプキンス・ユニバーシティ 常染色体優性多発性嚢胞腎疾患を治療するための嚢胞性線維症膜貫通コンダクタンス制御因子の調節因子

Also Published As

Publication number Publication date
WO2020216740A1 (en) 2020-10-29
JP2022529814A (ja) 2022-06-24
PH12021552680A1 (en) 2022-07-04
IL287392A (en) 2021-12-01
SG11202111739VA (en) 2021-11-29
US12383544B2 (en) 2025-08-12
BR112021021117A2 (pt) 2021-12-14
EP3958863C0 (en) 2024-07-03
CA3137445A1 (en) 2020-10-29
MA55752A (fr) 2022-03-02
EP3958863A1 (en) 2022-03-02
ES2982398T3 (es) 2024-10-16
US20220202802A1 (en) 2022-06-30
KR20220004111A (ko) 2022-01-11
GB201905711D0 (en) 2019-06-05
EP3958863B1 (en) 2024-07-03
AU2020263869A1 (en) 2021-12-23
JP7543304B2 (ja) 2024-09-02
CN113727711A (zh) 2021-11-30

Similar Documents

Publication Publication Date Title
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
DOP2021000179A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
ECSP18094790A (es) Piridinas sustituidas con heteroarilo y métodos de uso referencia cruzada a solicitudes relacionadas
ECSP20035590A (es) Derivado de oxi-fluoropiperidina como inhibidor de quinasa
CO2019004034A2 (es) Compuesto de piridina
EA201690094A1 (ru) Ингибиторы syk
BR112014008045A2 (pt) benzilindazóis substituídos para uso como inibidores de bub1 cinase no tratamento de doenças hiperproliferativas
BR112017003658A2 (pt) composto, mistura, métodos para tratamento de uma doença e para inibição de uma glicosidase, e, composição farmacêutica.
MX2017008048A (es) Derivados de 5-[(piperazin-1-il)-3-oxopropil]-imidazolidin-2,4-dio na como inhibidores de desintegrina y metaloproteinasa con motivos de trombospondina (adamts) para el tratamiento de osteoartritis.
EA201690153A1 (ru) Замещенные бензофуранильные и бензоксазолильные соединения и их применения
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
DOP2017000278A (es) Piridinas sustituidas y método de uso
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
CL2019002079A1 (es) Sales del inhibidor de pim quinasa; útiles en el tratamiento del cáncer. (divisional solicitud 201800611)
MX346143B (es) Ligandos del receptor ep1.
UY37774A (es) Compuestos 5-cianoindol sustituidos y usos de los mismos
MX2021012544A (es) Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de enfermedades renales.
NI202100055A (es) Formas de sal y cristalinas de un compuesto orgánico y composiciones farmacéutica del mismo.
BR112019004236A2 (pt) compostos para tratar doenças associadas a uma disfunção mitocondrial
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
MX2023004955A (es) Compuestos de aminotiazol deuterados como compuestos antiviricos.
UY39874A (es) Compuestos novedosos de estireno y un proceso para la preparación de los mismos.
BR112021022225A2 (pt) Composto, pró-droga e composição farmacêutica
AR132909A1 (es) Métodos de tratamiento de enfermedades inflamatorias